Host-Based Diagnostics for Acute Infections
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) is issuing a Request for Information (RFI) for Host-Based Diagnostics for Acute Infections. This RFI seeks industry collaboration to develop next-generation host-based assays for diagnosing disease etiology, prognosticating clinical outcomes, and directing therapeutic treatments for warfighters exposed to CBRN threats. This is for market research and planning purposes only; it is not a solicitation. Responses are due May 22, 2026.
Scope of Interest
CPE CBRND is conducting market research for its Advanced Differential Diagnostics (ADD) program. The focus is on identifying and advancing mature diagnostics (preferably Technology Readiness Level (TRL) 4 or higher) that utilize the warfighter's early response to pathogens, rather than targeting specific pathogens directly. Key areas of interest include:
- Predictive Diagnostics for Infection Complications: Assays predictive for Sepsis, SIRS, respiratory destabilization, or other acute complications from biowarfare agents, based on host biomarkers.
- Diagnostics to assist in Therapeutic Selection and Monitoring: Host biomarker-based diagnostics for precision medicine, treatment response, or ineffective therapeutics.
Ideal products should be small (handheld/backpack-sized), battery-operable, function in tropical environments, have an assay time under 70 minutes (ideally under 10 minutes), and demonstrate clinical sensitivity and specificity greater than 90% using peripheral blood or other minimally invasive samples.
Contract & Timeline
- Type: Request for Information (RFI) / Sources Sought
- Set-Aside: None specified (market research stage)
- Response Due: May 22, 2026, 7:00 PM ET
- Published: April 24, 2026
- Agency: DEPT OF DEFENSE / DEPT OF THE ARMY
Requested Information
Respondents are requested to submit a white paper (not exceeding three pages) and a separate one-page Quad Chart. The government will emphasize Technical Approach and Product Maturity and Regulatory and Clinical Status. Key areas to address in the white paper include:
- Technical Approach and Product Maturity: Product description, TRL justification, and diagnostic efficacy data summary.
- Regulatory and Clinical Status: History of FDA interactions, status of applications, and clinical trial/data history.
- Manufacturing and Supply Chain: Current capabilities, scalability strategy, and source of key starting materials.
- Company Profile and Vision: Corporate experience in product development and teaming strategy.
Additional Notes
This RFI is for planning purposes only and does not constitute a solicitation or commitment to contract. The government will not pay for information submitted. Do not include proprietary or classified information. Responses should be sent to usarmy.detrick.cpe-cbrnd.mbx.baa@army.mil with the subject line denoting the responding organization and RFI title. For inquiries, contact Keith Pereira (keith.d.pereira.civ@army.mil).